使用脑脊液生物标志物来诊断阿尔茨海默病:澳大利亚的观点
Dhamidhu Eratne1,2,3, Steven Collins2,4, Peter J Nestor5,6
1Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Frontiers in psychiatry
|December 20, 2024
概括
大脑脊髓液 (CSF) 生物标志物对于在澳大利亚诊断阿尔茨海默病 (AD) 是至关重要的. 建议更广泛地采用CSF生物标志物测试,以改善早期AD诊断,特别是使用新的疾病修饰疗法.
科学领域:
- 神经学 神经学
- 生物化学 生物化学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 大脑脊髓液 (CSF) 生物标志物是澳大利亚阿尔茨海默病 (AD) 唯一经过验证的生物流体诊断.
- 包括粉胺β,总和酸化在内的CSF分析,比标准评估更深入地了解AD病理生理学.
研究的目的:
- 倡导在澳大利亚临床实践中增加CSF生物标志物测试的利用率.
- 提供基于证据的指导,关于在AD诊断中适当使用CSF生物标志物的指导.
主要方法:
- 审查目前的临床实践和挑战在CSF生物标志物测试AD在澳大利亚.
- 与其他方法相比,对脊髓瘤生物标志物 (粉样β,,酸化) 的诊断价值的分析.
主要成果:
- 脑脊液生物标志物测试是一种安全且具有成本效益的AD诊断工具.
- 澳大利亚的临床采用有限归因于接入问题,腰部穿刺 (LP) 的感知入侵性和解释挑战.
结论:
- 疾病修饰疗法的出现需要更早,更准确的AD诊断.
- 在专家指导的支持下,扩大使用CSF生物标志物测试对于及时的AD管理和治疗至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162